434 results on '"Cahn, Avivit"'
Search Results
2. Incorporation of a Stress Reducing Mobile App in the Care of Patients With Type 2 Diabetes: A Prospective Study
3. Gestational diabetes and risk of future diabetes in a multi-ethnic population
4. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
5. Reported iodinated contrast media allergy is a risk factor for anaphylaxis-independent mortality in hospitalized patients
6. SGLT2 Inhibitors and Safety in Older Patients
7. Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
8. Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
9. Predictors and outcomes of diabetic foot ulcer infection with ESBL-producing bacteria in a large tertiary center
10. Complex rearrangement in TBC1D4 in an individual with diabetes due to severe insulin resistance syndrome
11. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
12. Role of Cannulated Prolactin Test in Evaluation of Hyperprolactinemia - A Retrospective Study
13. Cardio‐renal‐metabolic disease in primary care setting.
14. Prescription patterns in people who are frail
15. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
16. Glycemic Targets and Prevention of Chronic Complications
17. Comparison Of Hba1C Goals Proposed By An Algorithm To Those Set By Different Members Of Healthcare Teams Within The Dartmouth Hitchcock Health System
18. Alpelisib in Intractable Non–Islet-Cell Tumor Hypoglycemia
19. Enterococci in diabetic foot infections: Prevalence, Clinical Characteristics, and Outcomes
20. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes
21. Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58
22. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58
23. Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
24. RELATIONSHIP BETWEEN CYSTATIN C, CREATININE-BASED EGFR, CARDIOVASCULAR EVENTS AND KIDNEY OUTCOMES IN DECLARETIMI 58
25. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
26. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial
27. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
28. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial
29. New forms of insulin and insulin therapies for the treatment of type 2 diabetes
30. Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real‐life clinical practice
31. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
32. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial
33. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
34. The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care
35. Acute diabetic foot in post kidney transplantation patients receiving chronic immunosuppression—clinical presentation and outcomes
36. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
37. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
38. Consistency of Thyroid Imaging Reporting and Data System Reporting in Community-Based Imaging Centers Versus a Large Tertiary Hospital
39. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
40. The role of insulin pump therapy for type 2 diabetes mellitus
41. Digital health technology and diabetes management
42. Continuous subcutaneous insulin infusion—an opportunity for better care but not a “magic pill”
43. Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes
44. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
45. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
46. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
47. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
48. Angiogenic potential of mesenchymal stem cells derived from patients with diabetes seeded on decellularized micro fragments
49. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
50. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.